Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation

Introduction: Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder that is usually associated with mutations in the MECP2 gene. The most common mutations in the gene are p.R168X and p.T158M. The influence of X-chromosome inactivation (XCI) on clinical severity in patients with RTT with these mutations was investigated, taking into account the extent and direction of skewing. Methods: Female patients and their parents were recruited from the UK and Australia. Clinical severity was measured by the Pineda Severity and Kerr profile scores. The degree of XCI and its direction relative to the X chromosome parent of origin were measured in DNA prepared from peripheral blood leucocytes, and allele-specific polymerase chain reaction was used to determine the parental origin of mutation. Combining these, the percentage of cells expected to express the mutant allele was calculated. Results: Linear regression analysis was undertaken for fully informative cases with p.R168X (n = 23) and p.T158M (n = 20) mutations. A statistically significant increase in clinical severity with increase in the proportion of active mutated allele was shown for both the p.R168X and p.T158M mutations. Conclusions: XCI may vary in neurological and haematological tissues. However, these data are the first to show a relationship between the degree and direction of XCI in leucocytes and clinical severity in RTT, although the clinical utility of this in giving a prognosis for individual patients is unclear.

[1]  M. Schwartz,et al.  Increased skewing of X chromosome inactivation in Rett syndrome patients and their mothers , 2006, European Journal of Human Genetics.

[2]  R. Prescott,et al.  People with MECP2 mutation-positive Rett disorder who converse. , 2006, Journal of intellectual disability research : JIDR.

[3]  Carol Bower,et al.  Rett syndrome in Australia: a review of the epidemiology. , 2006, The Journal of pediatrics.

[4]  J. Christodoulou,et al.  p.R270X MECP2 mutation and mortality in Rett syndrome , 2005, European Journal of Human Genetics.

[5]  R. Hastings,et al.  Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype–phenotype associations in Rett syndrome , 2005, European Journal of Human Genetics.

[6]  N. C. Schanen,et al.  Does Genotype Predict Phenotype in Rett Syndrome? , 2005, Journal of child neurology.

[7]  P. Tam,et al.  Reduced proportion of Purkinje cells expressing paternally derived mutant Mecp2308 allele in female mouse cerebellum is not due to a skewed primary pattern of X-chromosome inactivation. , 2005, Human molecular genetics.

[8]  J. Christodoulou,et al.  X chromosome inactivation patterns in brain in Rett syndrome: implications for the disease phenotype , 2005, Brain and Development.

[9]  P. Tam,et al.  Distinct expression profiles of Mecp2 transcripts with different lengths of 3'UTR in the brain and visceral organs during mouse development. , 2005, Genomics.

[10]  T. Matsuishi,et al.  Methyl-CpG binding protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome: pathological mutations and polymorphisms , 2005, Brain and Development.

[11]  J. Christodoulou,et al.  Trisomy 21 and Rett syndrome: A double burden , 2004, Journal of paediatrics and child health.

[12]  Rodney C. Samaco,et al.  X-Chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2-/+ mouse brain. , 2004, Human molecular genetics.

[13]  Juan I. Young,et al.  X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of rett syndrome. , 2004, American journal of human genetics.

[14]  J Christodoulou,et al.  Refining the phenotype of common mutations in Rett syndrome , 2004, Journal of Medical Genetics.

[15]  T. Matsuishi,et al.  Patients with the R133C mutation: is their phenotype different from patients with Rett syndrome with other mutations? , 2003, Journal of medical genetics.

[16]  F. Hanefeld,et al.  Mutation analysis in the MECP2 gene and genetic counselling for Rett syndrome , 2003, Journal of medical genetics.

[17]  N. Laing,et al.  Effects of MECP2 mutation type, location and X‐inactivation in modulating Rett syndrome phenotype , 2003, American journal of medical genetics. Part A.

[18]  M. Schwartz,et al.  No correlation between phenotype and genotype in boys with a truncating MECP2 mutation , 2003, Journal of medical genetics.

[19]  M. Msall,et al.  Describing the phenotype in Rett syndrome using a population database , 2003, Archives of disease in childhood.

[20]  Y. Makita,et al.  The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome , 2001, Brain and Development.

[21]  A. Renieri,et al.  Preserved speech variants of the Rett syndrome: molecular and clinical analysis. , 2001, American journal of medical genetics.

[22]  N. Lévy,et al.  Segregation of a totally skewed pattern of X chromosome inactivation in four familial cases of Rett syndrome withoutMECP2 mutation: implications for the disease , 2001, Journal of medical genetics.

[23]  P. Huppke,et al.  MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. , 2001, American journal of human genetics.

[24]  J. Chelly,et al.  Parental origin of de novo MECP2 mutations in Rett syndrome , 2001, European Journal of Human Genetics.

[25]  T. Matsuishi,et al.  Mutation analysis of the methyl-CpG binding protein 2 gene (MECP2) in patients with Rett syndrome , 2000, Journal of medical genetics.

[26]  P. Jonveaux,et al.  MECP2 mutations account for most cases of typical forms of Rett syndrome. , 2000, Human molecular genetics.

[27]  P. Huppke,et al.  Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. , 2000, Human molecular genetics.

[28]  H. Zoghbi,et al.  Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes , 2000, Annals of neurology.

[29]  H. Zoghbi,et al.  Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. , 1999, American journal of human genetics.

[30]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[31]  J. Azofeifa,et al.  X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes , 1995, Human Genetics.

[32]  Subir Ghosh,et al.  Statistical Analysis With Missing Data , 1988 .

[33]  E. Hoffman,et al.  Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. , 2002, Mental retardation and developmental disabilities research reviews.

[34]  Mutation analysis of the methyl-CpG binding protein 2 gene ( MECP 2 ) in patients with Rett syndrome , 2000 .

[35]  H. Zoghbi,et al.  Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. , 1992, American journal of human genetics.

[36]  M. Lyon,et al.  X-chromosome inactivation as a system of gene dosage compensation to regulate gene expression. , 1989, Progress in nucleic acid research and molecular biology.

[37]  J. Graves,et al.  A two step model for mammalian X-chromosome inactivation. , 1985, Progress in clinical and biological research.